← Back to Search

Financial Incentives for Quitting Smoking (FIESTA II Trial)

N/A
Waitlist Available
Led By Joseph Ladapo, MD, PhD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
age ≥ 18 years
Be older than 18 years old
Must not have
are discharged to an institution (e.g., nursing home, long-term care facility)
are unable to provide informed consent, or do not have cognitive ability to enroll or participate in the study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether financial incentives can help smokers quit, by comparing three different approaches. They will also compare how well these approaches work in the short term and long term, and whether they are a good investment.

Who is the study for?
This trial is for adults over 18 who have smoked tobacco in the last month, are considering quitting smoking, and can consent in English or Spanish. They must have an active U.S. phone number and address. It's not for those using only smokeless tobacco, pregnant or breastfeeding individuals, people discharged to institutions like nursing homes, or anyone unable to consent.
What is being tested?
The study tests if financial rewards can help hospitalized smokers quit. Participants will receive smoking cessation counseling (Quitline), pharmacotherapy (like nicotine patches), and cash incentives for quitting or using these therapies effectively.
What are the potential side effects?
There may be no direct medical side effects from participating; however, common challenges when quitting smoking include nicotine withdrawal symptoms such as irritability, cravings, difficulty concentrating, increased appetite leading to weight gain.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am being discharged to a nursing home or long-term care facility.
Select...
I am able to understand and agree to participate in the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Smoking abstinence assessed by self-report and biochemically verified by salivary cotinine
Secondary study objectives
Long term return on investment of using financial incentives to promote smoking cessation (Cost analysis)
Quality of life as measured by PROMIS-29 Profile v2.0
Short term return on investment of using financial incentives to promote smoking cessation (Cost analysis)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Outcome-Based IncentivesExperimental Treatment3 Interventions
Group II: Goal-Directed IncentivesExperimental Treatment3 Interventions
Group III: Enhanced Usual CareExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
2015
N/A
~190
Smoking cessation counseling (Quitline)
2015
N/A
~190

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,564 Previous Clinical Trials
10,261,575 Total Patients Enrolled
NYU Langone HealthOTHER
1,409 Previous Clinical Trials
854,527 Total Patients Enrolled
Olive View-UCLA Education & Research InstituteOTHER
33 Previous Clinical Trials
878,779 Total Patients Enrolled

Media Library

Smoking cessation pharmacotherapy Clinical Trial Eligibility Overview. Trial Name: NCT03979885 — N/A
Quitting Smoking Research Study Groups: Goal-Directed Incentives, Outcome-Based Incentives, Enhanced Usual Care
Quitting Smoking Clinical Trial 2023: Smoking cessation pharmacotherapy Highlights & Side Effects. Trial Name: NCT03979885 — N/A
Smoking cessation pharmacotherapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT03979885 — N/A
~18 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top